14 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 14 of 14 clinical reviews.
TRICARE coverage for Rezdiffra (resmetirom) requires prior authorization and documented MASH diagnosis. Learn formulary tier, step therapy rules, appeal steps, and cost-saving options for military beneficiaries.
Compare Rezdiffra (resmetirom) pricing, mechanism, and evidence against other MASH treatment options, including insurance coverage patterns and a decision framework by fibrosis stage and comorbidity.
Evidence-based guide to food and supplement interactions with Rezdiffra (resmetirom), the first FDA-approved therapy for MASH. Covers absorption effects, thyroid supplements, fiber timing, and clinical recommendations.
A clinical review of resmetirom (Rezdiffra) future formulations, combination strategies, and Madrigal Pharmaceuticals' development pipeline for MASH treatment.
A clinical deep-dive into resmetirom (Rezdiffra) hair loss, alopecia, rash, and other dermatologic adverse effects reported in MAESTRO-NASH and post-marketing surveillance, with dosing context and management guidance.
Evidence-based missed-dose protocol for Rezdiffra (resmetirom), including timing rules, pharmacokinetic rationale, and clinical guidance for patients with MASH.
A guide to resmetirom absorption, distribution, metabolism, and excretion, covering liver-selective uptake, CYP2C8 pathways, drug interactions, and what MAESTRO-NASH data mean for dosing.
A physician-level guide to the Rezdiffra (resmetirom) pre-surgery hold window, including pharmacokinetics, thyroid-axis considerations, bleeding risk, anesthetic interactions, and a practical perioperative protocol.
A comprehensive review of resmetirom (Rezdiffra) real-world evidence from registries and post-marketing data, including mechanism of action, clinical effectiveness outside trial settings, and emerging safety signals.
Rezdiffra is not approved in Canada as of mid-2026: Madrigal filed a New Drug Submission with Health Canada, but no Notice of Compliance has been issued.
How to store Rezdiffra (resmetirom) tablets, the FDA-labeled shelf life and temperature range, what a temperature or moisture excursion means for a specific bottle, and when to call a pharmacist instead of guessing.
Rezdiffra dosing starts at 80 mg once daily with food for 12 weeks, then steps up to 100 mg daily as tolerated for adults with MASH and F2-F3 fibrosis.
Rezdiffra inhibits CYP2C8 and OATP1B1/1B3, raising levels of statins, pioglitazone and repaglinide; monitor thyroid drugs like levothyroxine and amiodarone closely.
Rezdiffra's 2024 approval came with liver injury monitoring requirements; trial data shows diarrhea, nausea, and gallbladder events as the main risks so far.